louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05185882: The Effect of Different Focusing Methods on Muscle Activity
Official title: The Effect of Different Focusing Methods on Muscle Activity During The Single Leg Squat Movement
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Knee Injuries and Disorders
Keywords: single leg squat
muscular activity
knee alignment
Lead sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy Volunteers

Brief summary: The aim of this study is to compare the effects of different focusing methods on muscular activity

Detailed description: After the first data collecting ( Demographic data, Inclusion criteria) surface electromyography EMG evaluations will be taken from 6 muscles( Vastus Medialis, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Semitendinosus, Gluteus Medius). These recordings will be taken in 3 different circumstances: 1- Without a focusing method 2- With an external focus and 3- With an internal focus

Eligibility criteria: Inclusion Criteria:

* Being between the ages of 18-25
* Having a Body Mass Index between 18.5-24.9

Exclusion Criteria:

* Having trauma/surgery involving the lower extremity in the last 6 months or having any disorder affecting hip and knee muscle function
* Foot Posture Index score not being between 0 and +5
* Hamstring Flexibility- Sit and Reach Test score greater than +5 cm
* Restricted ankle dorsiflexion angle (It will be expected to be at least 5 degrees more than neutral)

Primary outcomes:
measure: Surface Electromyography
timeFrame: Procedure (During the intervention)
Secondary outcomes:
measure: Foot Posture Index
timeFrame: Baseline, for inclusion criteria
measure: Sit and Reach Test
timeFrame: Baseline, for inclusion criteria
measure: Gluteus Medius Muscle Dynamometer Assessment
timeFrame: Baseline, for inclusion criteria
measure: Ankle Dorsi Flexion Goniometer Assessment
timeFrame: Baseline, for inclusion criteria
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Emre Serdar Atalay
state: İ̇stanbul
Study officials:
affiliation: Saglik Bilimleri Universitesi
name: Emre Serdar Atalay, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00327782: Palliative Care of Children With End-Stage Heart Failure
Official title: Palliative Care of Children With End-Stage Heart Failure
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Congenital Disorders
Keywords: pediatric
palliative care
end stage heart failure
Lead sponsor: Children's Healthcare of Atlanta
Sponsor class: OTHER
First posted: 2006-05-19
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: Palliative care in pediatric oncology and neurology is well described in the literature. There is a lack of information on the care of children terminally ill due to heart failure. A significant number of children are diagnosed with terminal heart failure for which palliative care is required.

Objective:

To describe palliative care of children over one year of age with end-stage heart failure, including need for and types of pain control, hospice use, need for and use of home nursing and quality of life issues.

Detailed description: Methods:

Retrospective chart review of all children over one year of age diagnosed with end-stage heart failure between January 1, 1995 and December 31, 2005 at Children's Healthcare of Atlanta, Egleston Hospital, followed by Sibley Heart Center Cardiology.

Patient variables taken from the medical charts will include:

Diagnosis Age, gender Medications Prior surgery or transplantation Associated conditions such as muscular dystrophy, renal failure

Practice variables taken from the medical charts will include:

Hospice care provided Home inotropic infusions Medications administered for pain Social work/psychology evaluation DNR status

Statistics:

Number of patients receiving home nursing, involved in hospice, treated with pain medications, home oxygen or home inotropes.

Eligibility criteria: Inclusion Criteria:

* Any patient between 1 - 18 years of age (inclusive) Any patient with end stage heart disease Treated at Egleston Hospital, Children's Healthcare of Atlanta Followed by Sibley Heart Center Cardiology

Exclusion Criteria:

* Those who do not meet inclusion criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Children's Healthcare of Atlanta
state: Georgia
Study officials:
affiliation: Emory University SOM, Children's Healthcare of Atlanta
name: William T Mahle, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00637182: Gynecomastia Extension Study
Official title: An OptioExtension of Trial 1033US/0006 to Assess Safety, Tolerability, Efficacy of Anastrozole (ZD1033, Arimidex™) in Treatment of Gynecomastia in Pubertal Boys Given Placebo and to Conduct a Long-Term Safety Follow-Up of Non-Responding Subjects Given Anastrozole in the Previous Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Gynecomastia
Keywords: Gynecomastia
Anastrazole
Arimidex
Pubertal
males
boys
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-03-17
Sex: MALE
Minimum age (years): 11
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another anastrozole study).


Eligibility criteria: Inclusion Criteria:

* Subjects must have entered Trial 1033US/0006 and completed 6 months of treatment and one month of follow-up.
* Subjects must have gynecomastia, with one breast measuring at least 3 cm in diameter.

Exclusion Criteria:

* Subjects who have been given medications known to cause gynecomastia within the previous 3 months

Primary outcomes:
measure: Change in linear dimensions of the breast
Secondary outcomes:
measure: Change in breast tenderness
Other outcomes:
Locations:
Study officials:
affiliation: Baystate Medical Center-Children's Hospital
name: Edward O Reiter, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02506582: The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control
Official title: The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prediabetes
Newly Diagnosed Type 2 Diabetes
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2015-07-23
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this randomized, double-blind, placebo-controlled study was to determine whether jerusalem artichoke and fermented soybeans powder mixture is effective in the control of blood glucose level in subjects with prediabetes or newly diagnosed type 2 diabetes.

Detailed description: The objective of this clinical study was to evaluate the effect of jerusalem artichoke and fermented soybean powder mixture supplementation on blood glucose. A randomized, double-blinded, placebo-controlled study was conducted on 60 subjects with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly diagnosed type 2 diabetes. The subjects were randomly assigned to either a group ingesting 40 g jerusalem artichoke and fermented soybean powder mixture supplementation daily or a placebo group for 12-week. We assessed fasting and postprandial levels of glucose.

Eligibility criteria: Inclusion Criteria:

1. All subjects were with prediabetes (IFG or IGT) or newly diagnosed type 2 DM (T2DM) no taking medicine. IFG was defined as fasting glucose between 100 and 125 mg/dL and IGT was defined as 2-h OGTTs glucose levels 140-199 mg/dL. Newly diagnosed type 2 diabetes was defined as fasting glucose ≥126 mg/dL or 2-h OGTTs level ≥ 200 mg/dL.

Exclusion Criteria:

1. glucose lowering medications or insulin injections;
2. abnormal liver or renal function;
3. chronic stomach and intestines disease;
4. chronic alcoholism;
5. pregnancy or intending to become pregnant during time of study.
6. complications;
7. an occupation that could be dangerous if hypoglycemia should occur.

Primary outcomes:
measure: Blood glucose level by 2-h oral glucose tolerance tests (OGTTs)
timeFrame: 12 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Yonsei University
name: Jong Ho Lee, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05848882: Removable Devices in Palatal Expansion
Official title: Comparison Between Removable Devices in Palatal Expansion: a Randomized Open Label Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Palatal Expansion Technique
Keywords: elastodontic device
growing patients
transversal palatal discrepancies
Lead sponsor: University of L'Aquila
Sponsor class: OTHER
First posted: 2023-05-08
Enrollment: 70
Sex: ALL
Minimum age (years): 9
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial si to compare two removable devices used to treat the transversal discrepancies in growing patients.

The main questions it aims to answer are:

* the efficacy of the two devices in the palatal expansion
* the neuromuscolar effects developed on the stomatognatic system Participants will be instructed in the use and maintenance of the devices and will be checked every 15-30 days for one year.


Eligibility criteria: Inclusion Criteria:

skeletal class I relationship, molar class I relationship; complete eruption of upper first premolars ; presence of unilateral or bilateral cross bite (falling within grade 3 IOTN index)

Exclusion Criteria:

IOTN index \>4; presence of temporomandibular disorders, epilepsy, systemic diseases, periodontal disease, absence of written informed consent signed by parents/legal guardians

Primary outcomes:
measure: Palatal first premolars width
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: L'Aquila
country: Italy
facility: Dipartimento MeSVA
state: Aq
Study officials:
References:
Clinical trial NCT04073082: Safety and Efficacy of Laser Therapy in Gynaecology
Official title: Safety and Efficacy of Er:YAG and Nd:YAG Laser Therapy in Gynecology: A Retrospective Case Series.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Herpes Genitalis
Genital Wart
Lichen Sclerosus
Cervical Intraepithelial Neoplasia
Labial Reduction Surgery
Episiotomy Scar
Bartholin Cyst
Hidradenitis Suppurativa
Lead sponsor: Juna d.o.o.
Sponsor class: INDUSTRY
First posted: 2019-08-29
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Retrospective study assessing the safety and efficacy of laser use in treatment of different gynecology indications.

Brief summary: The aim of this study is to retrospectively evaluate the effectiveness and safety of Er:YAG laser for treatment of different gynecological indication, e.g. genital lesions, Bartholin's cyst, condyloma, episiotomy scars, lesions of hydradenitis suppurativa and use of laser in genital surgery used in private practice.


Eligibility criteria: Inclusion Criteria:

* patients with any of the selected gynecology indications, treated with laser in the period 2013-2018
* signed informed consent

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Safety - occurence of adverse effects.
timeFrame: [1 year]
measure: Efficacy - number of laser treatments.
timeFrame: [1 year]
Secondary outcomes:
Other outcomes:
Locations:
city: Ljubljana
country: Slovenia
facility: Juna
Study officials:
affiliation: Specialist in obstetrics and gynecology
name: Urška Urska.Bizjak-Ogrinc@juna.si, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00707382: Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment
Official title: A Three-armed Randomised Controled Trial on the Effect of Genotyping for CYP450 Polymorphisms and Intense Clinical Monitoring on Antipsychotic Drug Treatment.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Keywords: Pharmacogenetics
Compliance
Antipsychotic drugs
Schizophrenia
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
Collaborators: name: Bispebjerg Hospital
name: Research Unit, Psyciatric Centre Bispebjerg
name: Research Institute of Biological Psychiatry,Psychiatric Centre Sct. Hans
name: Danish Centre for Health Technology Assessment
name: The Ministry of Health and Prevention, Denmark
name: TrygFonden, Denmark
First posted: 2008-06-30
Enrollment: 311
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine whether genotyping for CYP2D6 and 2C19 polymorphisms or intense clinical monitoring of treatment and adverse effects improves the antipsychotic treatment in patients with schizophrenia. This study is designed as a three-armed prospective randomized controlled clinical trial and includes 300 patients with schizophrenia. Patients are followed for a period of one year.

During the study period the following effect measures are registered:

* Time to discontinuation of all antipsychotic medications
* Number of changes in medication dose
* Number of changes in medication
* Compliance (patients´ adherence to medical treatment)
* Clinical symptoms
* Adverse effects


Eligibility criteria: Inclusion Criteria:

* Diagnosed with schizophrenia
* Able to give written informed consent

Exclusion Criteria:

* Genotyped prior to inclusion

Primary outcomes:
measure: Time to discontinuation of initial antipsychotic treatment
timeFrame: one year
Secondary outcomes:
measure: Compliance
timeFrame: one year
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Clinical Pharmacology, Bispebjerg Hospital and Research Unit, Psychiatric Centre Bispebjerg
Study officials:
affiliation: Department of Clinical Pharmacology, Bispebjerg University Hospital
name: Gesche Jürgens, MD, phd
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jurgens G, Andersen SE, Rasmussen HB, Werge T, Jensen HD, Kaas-Hansen BS, Nordentoft M. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial. JAMA Netw Open. 2020 Dec 1;3(12):e2027909. doi: 10.1001/jamanetworkopen.2020.27909.
Clinical trial NCT02325882: The Postoperative Analgesic Effect of Combination With Dexmedetomidine in Fentanyl-based Intravenous Patient Controlled Analgesia Compared With Conventional Thoracic Epidural and Intravenous Patient Controlled Analgesia After Radical Open Gastrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2014-12-25
Enrollment: 171
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study to test hypothesis that addition of dexmedetomidine to fentanyl based intravenous patient controlled analgesia (PCA) improves postoperative pain compared with conventional thoracic epidural and intravenous patient controlled analgesia after radical open gastrectomy.


Eligibility criteria: Inclusion Criteria:

1. ASA class I-II
2. obtaining written informed consent from the parents
3. aged 20-65 years who were undergoing radical open gastrectomy

Exclusion Criteria:

1. abdominal surgery previously
2. patient who refuse the patient controlled analgesia
3. unstable angina or congestive heart failure
4. uncontrolled hypertension (diastolic bp\>110mmHg)
5. coagulopathy
6. hepatic failure
7. renal failure
8. bradycardia on EKG (under 50 bpm)
9. Ventricular conduction abnormality
10. drug hyperactivity
11. neurological or psychiatric illnesses
12. mental retardation
13. patients who can't read the consent form due to illiterate or foreigner 14.infection

15. pregnant 16. obesity (BMI \> 30kg/m2)

Primary outcomes:
measure: Postoperative pain
timeFrame: 48 hours after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine
Study officials:
References:
Clinical trial NCT00917982: The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients
Official title: The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Strabismus
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2009-06-11
Sex: ALL
Minimum age (years): 3
Maximum age (years): 7
Standard ages: CHILD

Brief summary: Vision therapy (VTO) is a group of non-surgical treatment helping patients in 3 subjects;1)increasing the the visual acuity 2)improving the mechanical skills resulting in increasing the power of extraocular muscles,biocular vision,peripheral vision 3) increasing the perceptual skills making the brain to percept the colour and visual memory better.In this study we are going to compare the effect of vision therapy /orthoptic on motor \& sensory of the 3 to 7 years old strabismic patients


Eligibility criteria: Inclusion Criteria:

* 3\<age\<7
* Congenital isotropia

Exclusion Criteria:

* Muscular disease
* General ocular and systemic disease
* Seizure
* Visual Acuity \< 60/20
* Nystagmus
* Follow up less than 3 months after surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Ophthalmic Research Center
Study officials:
References:
Clinical trial NCT03602482: Standing Cognition and Co-morbidities of POTS Evaluation
Official title: Standing Cognition and Co-morbidities of POTS Evaluation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postural Tachycardia Syndrome
Ehlers-Danlos Syndrome
Keywords: postural tachycardia syndrome
cognition
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
Collaborators: name: Dysautonomia International
First posted: 2018-07-26
Enrollment: 139
Sex: ALL
Minimum age (years): 13
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to evaluate cognition in patients with postural tachycardia syndrome (POTS) while lying down and standing and to assess the prevalence of hypermobile Ehlers-Danlos Syndrome in POTS.


Eligibility criteria: Inclusion Criteria:

* Previously diagnosed with POTS, or healthy control
* Age between 13-60 years
* Participants may be any race, ethnicity, sex, or gender
* Able and willing to provide informed consent

Exclusion Criteria:

* Inability to give, or withdrawal of, informed consent
* Age ≤ 13 or ≥ 61 years
* Prisoners
* Unable to stand

Primary outcomes:
measure: Executive Function (Stroop Word-color Test)
timeFrame: 1 hour
Secondary outcomes:
measure: Attention Score Using Cogstate Identification Task
timeFrame: 1 hour
measure: Number of Participants With Hypermobile Ehlers-Danlos Syndrome (hEDS)
timeFrame: 1 hour
measure: Heart Rate Standing Minus Heart Rate Supine
timeFrame: 1 hour
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Penn State College of Medicine
state: Pennsylvania
Study officials:
affiliation: Penn State College of Medicine
name: Amanda J Miller, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04334382: Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19
Official title: Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: COVID-19
Keywords: SARS-Co-V-2
Hydroxychloroquine
Azithromycin
Lead sponsor: Intermountain Health Care, Inc.
Sponsor class: OTHER
Collaborators: name: University of Utah
name: Utah Department of Health
First posted: 2020-04-06
Enrollment: 1550
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19.


Eligibility criteria: Inclusion Criteria:

* Adult, Age\>44 years, competent to provide consent
* Confirmed COVID-19, via a positive nucleic acid assay for COVID-19 within the last 7 days

Exclusion Criteria:

* Participants already prescribed chloroquine, hydroxychloroquine, or azithromycin
* Allergy to hydroxychloroquine or azithromycin
* History of bone marrow transplant
* Known G6PD (Glucose-6-Phosphate Dehydrogenase Deficiency) deficiency
* Chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or Glomerular Filtration Rate \< 20ml/min/1.73m2
* Liver disease (e.g. Child Pugh score ≥ B or AST (Aspartate Transaminase)\>2 times upper limit)
* Psoriasis
* Porphyria
* Known cardiac conduction delay (QTc \> 500mSec) or taking any prescription medications known to prolong QT interval
* Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone
* Prisoner
* Weight \< 35kg
* Inability to follow-up - no cell phone or no address or not Spanish or English speaking
* Receipt of any experimental treatment for SARS-CoV-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation
* No symptoms attributable to COVID-19
* Pregnant or nursing

Primary outcomes:
measure: Hospitalization within 14 days of enrollment
timeFrame: From enrollment to 14 days after enrollment
Secondary outcomes:
measure: Duration of COVID-19-attributable symptoms
timeFrame: From enrollment to 14 days after enrollment
measure: Hospital-free days at 28 days
timeFrame: Admission (day 1) to 28 days after admission (day 28)
measure: Ventilator-free days at 28 days
timeFrame: Admission (day 1) to 28 days after admission (day 28)
measure: ICU-free days at 28 days
timeFrame: Admission (day 1) to 28 days after admission (day 28)
Other outcomes:
Locations:
city: Murray
country: United States
facility: Intermountain Medical Center
state: Utah
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
Study officials:
affiliation: Intermountain Health Care, Inc.
name: Brandon Webb, MD
role: PRINCIPAL_INVESTIGATOR
References: